Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03108846 · ClinicalTrials.gov registry record · Phase 3
Escitalopram for Agitation in Alzheimer's Disease
A Phase 3 study of Dementia, sponsored by JHSPH Center for Clinical Trials.
- Active
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT03108846: Active Phase 3 study of Dementia, sponsored by JHSPH Center for Clinical Trials.
NCT03108846 is a Phase 3 study of Dementia that is active but no longer recruiting, run by JHSPH Center for Clinical Trials. The registered enrollment target is 187 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03108846, a Phase 3 study of Dementia, is active but no longer recruiting, sponsored by JHSPH Center for Clinical Trials.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
Primary Outcome
Clinical Global Impression of Change
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram
Study Locations (20)
Arkansas
- Biomedical Research Foundation - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
California
- University of California Los Angeles/VA Greater Los Angeles Healthcare System - Los Angeles
- University of Southern California Keck School of Medicine Memory and Aging Center - Los Angeles
Maryland
- Maryland VA Health Care System - Baltimore
- Johns Hopkins University School of Medicine, Bayview Medical Center - Baltimore
New York
- Columbia University - New York
- University of Rochester Medical Center - Rochester
Pennsylvania
- Abington Neurological Associates, Ltd - Abington
- Alzheimer Disease Research Center; University of Pittsburgh - Pittsburgh
Texas
- Baylor AT&T Memory Center - Dallas
- UT Health San Antonio - San Antonio
Arizona
- Banner Sun Health Research Institute - Sun City
Florida
- Miami Jewish Health Systems - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2025-05 |
| Phase | Phase 3 |
What the registry record for NCT03108846 still lists
NCT03108846 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Dementia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03108846 names 20 study sites across 14 states, led by Arkansas, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT03108846 about?
NCT03108846 is a clinical study titled "Escitalopram for Agitation in Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
What is the current status of trial NCT03108846?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2018-01-03. Estimated completion is 2025-05.
What conditions does trial NCT03108846 study?
This clinical trial studies the following conditions: Dementia.
What interventions are being tested in trial NCT03108846?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT03108846?
This trial is sponsored by JHSPH Center for Clinical Trials, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03108846 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03108846's enrollment target sits among peer trials
187 95th of 199 higher than 105 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACHIEVE Brain Health Follow-Up Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
ACTIVE NOT RECRUITING · Phase 3
-
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Preventing Cognitive Decline With Alternative Therapies
COMPLETED · Phase 3
-
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
COMPLETED · Phase 3
-
High Intensity Light Therapy in Alzheimer's Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI